Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia

When there’s no head-to-head trial between two drugs, a network meta-analysis can compare them indirectly. This one pits the two PCSK9 inhibitors — evolocumab and alirocumab — against each other and against ezetimibe.

The finding: evolocumab lowered LDL more than alirocumab (by roughly 14–20% depending on the alirocumab dose) and more than ezetimibe, with broadly similar adverse-event rates. It challenges the assumption that the two PCSK9 inhibitors are interchangeable.

The practical takeaway is that, for patients needing maximal LDL lowering, the choice between PCSK9 inhibitors may not be a wash — evolocumab showed a larger reduction in these indirect comparisons. The status-quo angle is its potential to influence formularies and payer decisions.

We rate the evidence moderate: methodologically rigorous, but built on indirect comparisons rather than a head-to-head trial — and several authors are employed by evolocumab’s manufacturer (Amgen), a conflict that warrants real caution given the result favors their drug. Its clinical significance is moderate — useful comparative input for drug selection, but the sponsorship and indirect design temper how much weight the evolocumab-favoring conclusion should carry.